UBS Global Biopharma Conference 2026
Logotype for MannKind Corporation

MannKind (MNKD) UBS Global Biopharma Conference 2026 summary

Event summary combining transcript, slides, and related documents.

Logotype for MannKind Corporation

UBS Global Biopharma Conference 2026 summary

17 Nov, 2026

Portfolio and capital deployment

  • Portfolio spans United Therapeutics royalties and manufacturing, AFREZZA, FUROSCIX, and the inhaled nintedanib pipeline.

  • Management expects profitability in Q4 2026 and for 2027, following a year of investment for growth; capital may fund pipeline development, existing products, M&A, or debt reduction.

  • United Therapeutics-related royalties, milestones, and manufacturing are expected to generate over $1B in revenue through 2030.

  • Future business development focus includes nephrology, cardiology, endocrinology, pulmonary and respiratory areas, and complex drug-device combinations beyond inhalation.

FUROSCIX and ReadyFlow

  • ReadyFlow received approval in Q3 2026; within its first six weeks, nearly 75%-80% of patients converted from the on-body infusor, several quarters ahead of expectations.

  • Management expects Q4 2026 to be the strongest quarter ever for ReadyFlow and the overall business.

  • ReadyFlow is positioned to expand FUROSCIX use into hospitals; management cited heart failure or fluid overload as accounting for 40%-50% of hospitalizations.

  • A 40 mg presentation could broaden prescribing among more cautious physicians, while aggressive diuresis users may favor 120 mg or 160 mg doses.

  • 2027 FUROSCIX indicators will include prescriber count, breadth of prescribing, and use in hospital versus retail or community settings.

United Therapeutics partnership and DPI platform

  • United Therapeutics is advancing TYVASO DPI and pulmonary fibrosis opportunities, with PPF next; management sees the collaboration as having potential to continue for another decade or two.

  • IPF is expected to launch first with nebulized delivery, potentially in 2027; a DPI may support compliance and market expansion, subject to future development.

  • MannKind's IPF powder study showed tolerability, with cough not prompting discontinuations, supporting confidence in DPI use for future phase III development.

  • Manufacturing capacity for TYVASO has been scaled with United Therapeutics; the nintedanib program is already manufactured at scale, with filling equipment in place and lower incremental capital needs.

  • The DPI platform uses FDKP to carry drug payloads; formulations vary by product, while the inhaler is designed to slow powder delivery and reduce dependence on inhalation effort.

Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.
All investor relations material. One API.
Learn more

Latest events from MannKind